Status
Conditions
Treatments
About
Patients will be randomised to receive CAD/CAM metallic removable partial denture (RPD) followed by Conventional metallic RPD (Group A), or the opposite sequence (Group B), with a 3-month wear duration for each denture and washout period for one week. Patients will be recalled at base line and 3 months following prosthetic insertion to evaluate Oral health related quality of life. It is hypothesized that removable partial dentures with CAD/CAM metallic RPD frameworks would improve Oral health related quality of life than those with Conventional metallic RPD frameworks.
Full description
Eligible patient will be selected from outpatient clinic in removable prosthodontics department clinic. Patients will be informed of the nature of the research work and informed consent will be obtained from each of them. Only motivated patients who shows cooperation will participate in the study. Patients will be randomised to receive CAD/CAM metallic RPD followed by Conventional metallic RPD (Group A), or the opposite sequence (Group B), with a 3-month wear duration for each denture and washout period for one week. Patients will be recalled at base line and 3 months following prosthetic insertion to evaluate Oral health related quality of life and cost effectiveness.
Patients will be subjected to:
CAD/CAM metallic RPD:
Conventional metallic RPD:
Criteria for discontinuing or modifying intervention:
Regardless of any decision to modify their assigned intervention, study participants will be retained in the trial whenever possible to enable follow up data collection and prevent missing data. If periodontitis is reported during follow up period, a suitable mouthwash will be given to the patient, who will be recalled regularly to closely observe the changes. If periodontitis continue, patient will be advised to stop wearing the prosthesis for two weeks till inflammation subsides and supra and sub gingival scaling and root planning will be carried out. Continued bone loss or inflammation might dictate trial discontinuation. If inflammation related to fitting surface of the denture or to any of the components was reported during follow up period, the RPD will be checked for any pressure areas to be relieved, a suitable mouthwash will be given to the patient and as mentioned before; the patient will be recalled regularly to closely observe the changes. The period of discontinuing the treatment will be included in the follow up period.
Strategies to improve adherence to intervention:
The patients will be asked to attend regular follow up visits and their adherence to the oral hygiene instructions will be monitored. Any signs of inflammation as redness or profuse plaque will be photographed and shown to the patient. This will reflect the importance of the oral hygiene measures.
Patients will receive phone calls from secretary to remind him/her of the follow up visits. Address of the patients will be recorded, in case the patient did not show up a home visit will be considered.
Patients will be recalled at one and 3 months after RPD insertion and whenever they have a complaint.
Sample size:
The investigators are planning a study of a continuous response variable from matched pairs of study subjects. Prior data indicate that the difference in the response of matched pairs is normally distributed with a standard deviation of 25.7. If the true difference in the mean response of matched pairs is 15, the investigators will need to study 19 pairs of subjects to be able to reject the null hypothesis that this response difference is zero with probability (power) 0.8. The Type I error probability associated with this test of this null hypothesis is 0.05.
Recruitment:
Another eligibility examination will be made by the researcher and the research will be discussed with all patients and only motivated patient will join the research.
B) Assignment of interventions
Allocation:
Randomization:
Allocation concealment mechanism:
Every participant will grasp an opaque sealed opaque envelop from a box. The envelope will contain a number that corresponds to the treatment. Being opaque and sealed ensures allocation concealment.
Implementation (HF) is the person who will generate the allocation sequence centrally and who is responsible for ensuring proper randomization and allocation concealment.
Masking/blinding:
Care provider, participants, and statistician will be blinded.
C) Data collection, management, and analysis:
Data collection methods:
Plans for assessment and collection of outcome:
The collected data whether personal or numerical will be stored on excel sheets as an electronic copy and printed hard copy sheets. The primary outcome data will be collected before RPD insertion as baseline and then after insertion with one month and 3 months. While, the secondary outcome data will be collected before RPD insertion. Treatment will be coded in the questionnaire as A & B.
Plans to promote participant retention and complete follow-up:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
19 participants in 2 patient groups
There are currently no registered sites for this trial.
Central trial contact
tarek salah ali, assistant lecturer
Start date
Oct 01, 2024 • 7 months ago
End date
Dec 01, 2024 • 5 months ago
Today
May 05, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal